Universal Influenza Vaccines 2021

13-16 April 2021, Richard Doll Building, University of Oxford, Oxford, UK

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

URGENT ANNOUNCEMENT:

Due to the current COVID-19 crisis, UIV 2020 has been postponed from 29-30 April – 1 May to 13-16 April 2021.
One important development relating to the UIV 2021 scientific programme is that there will be an additional COVID-19 Vaccine day (Friday 16th April 2021) for additional sessions on ‘Updating the community on the current Covid-19 vaccines development work currently underway in Oxford, London and elsewhere’.

There will also be a focus on the potential problems that may arise with an overlap between the winter 2020/21seasonal influenza period and the ongoing worldwide Covid-19 pandemic and a potential Autumn second wave. Everyone is working hard to find a safe and effective Covid-19 vaccine and this extra day of sessions will be an important contribution to this effort.

If you wish to offer a presentation for this Covid-19 Vaccine Day on Friday 16th April 2021 then please contact me as soon as possible via the participation section.

John Herriot
UIV 2021 Secretariat

Join the conversation on Twitter – #UIV2021

Influenza viruses cause seasonal epidemics as well as pandemics and are a significant concern for human health. Current influenza vaccines show efficacy when they are antigenically well matched to circulating strains. Seasonal influenza viruses undergo antigenic drift at a high rate and, therefore, current vaccines have to be reformulated and readministered on an annual basis. Mismatches between vaccine strains and circulating strains frequently occur, significantly decreasing vaccine efficacy. In addition, current seasonal influenza virus vaccines have limited efficacy against newly emerging pandemic viruses. A universal influenza virus vaccine that induces long-term protection against all influenza virus strains would abolish the need for annual readministration of seasonal influenza virus vaccines and would significantly enhance our pandemic preparedness.

UIV 2021 – this new forum will offer researchers an opportunity to discuss the characteristics of universal influenza vaccines, their potential target antigens, and critical aspects to consider on the path to successfully developing such universal influenza virus vaccines.

The UIV 2021 Scientific Advisory Panel are calling for abstracts for both oral and poster presentation at the meeting – please see the participation page for abstract submission details.

Scientific Advisory Panel

UIV 2021 Conference Chairman:
Sarah Gilbert (Jenner Institute, University of Oxford, Oxford, UK)

Ted Ross (University of Georgia, Athens, Georgia, USA)
Sean Tucker (VAXART Inc., South San Francisco, California, USA)
John Oxford (Queen Mary University of London, London, UK)
Rob Lambkin-Williams (Virology Consult, London, UK)
Christopher Chadwick (World Health Organization, Geneva, Switzerland)
Pamuk Bilsel (FluGen Inc., Madison, Wisconsin, USA)
Othmar Engelhardt (NIBSC, South Mimms, Potters Bar, UK)
Tobias Kamphuis (Janssen Vaccines, Leiden, The Netherlands)
Anke Huckriede (University of Groningen, Groningen, The Netherlands)
Ron Babecoff (BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel)
Tamar Ben-Yedidia (BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel)
Harry Kleanthous (Gates Foundation, Seattle, Washington, USA)
Baozhong Wang (Georgia State University, Atlanta, Georgia, USA)
Emanuele Montomoli (VisMederi Srl, Siena, Italy)
Otfried Kistner (VisMederi, Siena, Italy)
Joanna Waldock (NIBSC, South Mimms, Potters Bar, UK)
Vivek Shinde (Novavax Inc, Rockeville, Maryland, USA)
Yuri Vasiliev (St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)
Shan Lu (University of Massachusetts, Worcester, Massachusetts, USA)

 

UIV 2021 Delegates

Login details will be supplied after you have registered for the event.


UIV 2021 Sponsors

  • Izon Science
  • ISIRV
  • BiondVax
  • The Native Antigen Company
  • DNAvaccine.com
  • Sanofi Pasteur
  • NanoFCM
  • APACI
  • FluConsult
  • Vaxart
  • VisMederi

UIV 2021 Mailing List

Name
E-mail Address
What is 3+2-1?